569 related articles for article (PubMed ID: 33868289)
1. Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation.
Machuldova A; Holubova M; Caputo VS; Cedikova M; Jindra P; Houdova L; Pitule P
Front Immunol; 2021; 12():651751. PubMed ID: 33868289
[TBL] [Abstract][Full Text] [Related]
2. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
[TBL] [Abstract][Full Text] [Related]
3. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
Front Immunol; 2018; 9():1282. PubMed ID: 29963042
[TBL] [Abstract][Full Text] [Related]
4. NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML.
Schlegel P; Ditthard K; Lang P; Mezger M; Michaelis S; Handgretinger R; Pfeiffer M
J Immunol Res; 2015; 2015():473175. PubMed ID: 26236752
[TBL] [Abstract][Full Text] [Related]
5. A disease-linked
Zuo J; Willcox CR; Mohammed F; Davey M; Hunter S; Khan K; Antoun A; Katakia P; Croudace J; Inman C; Parry H; Briggs D; Malladi R; Willcox BE; Moss P
Sci Signal; 2017 May; 10(481):. PubMed ID: 28559451
[TBL] [Abstract][Full Text] [Related]
6. Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma.
Xuan XY; Zhang JF; Hu GM; Li QR; Liu PP; Du Y
Cancer Gene Ther; 2015 Jul; 22(7):368-74. PubMed ID: 26113176
[TBL] [Abstract][Full Text] [Related]
7. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities.
Diermayr S; Himmelreich H; Durovic B; Mathys-Schneeberger A; Siegler U; Langenkamp U; Hofsteenge J; Gratwohl A; Tichelli A; Paluszewska M; Wiktor-Jedrzejczak W; Kalberer CP; Wodnar-Filipowicz A
Blood; 2008 Feb; 111(3):1428-36. PubMed ID: 17993609
[TBL] [Abstract][Full Text] [Related]
8. Role of NKG2D ligands and receptor in haploidentical related donor hematopoietic cell transplantation.
Petersdorf EW; McKallor C; Malkki M; He M; Spellman SR; Hsu KC; Strong RK; Gooley T; Stevenson P
Blood Adv; 2023 Jun; 7(12):2888-2896. PubMed ID: 36763517
[TBL] [Abstract][Full Text] [Related]
9. KLF4-mediated upregulation of the NKG2D ligand MICA in acute myeloid leukemia: a novel therapeutic target identified by enChIP.
Alkhayer R; Ponath V; Frech M; Adhikary T; Graumann J; Neubauer A; von Strandmann EP
Cell Commun Signal; 2023 May; 21(1):94. PubMed ID: 37143070
[TBL] [Abstract][Full Text] [Related]
10. Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing.
Vulpis E; Loconte L; Cassone C; Antonangeli F; Caracciolo G; Masuelli L; Fazio F; Petrucci MT; Fionda C; Soriani A; Cerboni C; Cippitelli M; Santoni A; Zingoni A
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298418
[TBL] [Abstract][Full Text] [Related]
11. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
12. Diversity and characterization of polymorphic 5' promoter haplotypes of MICA and MICB genes.
Cox ST; Madrigal JA; Saudemont A
Tissue Antigens; 2014 Sep; 84(3):293-303. PubMed ID: 24962621
[TBL] [Abstract][Full Text] [Related]
13. The MICA-129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation.
Isernhagen A; Malzahn D; Viktorova E; Elsner L; Monecke S; von Bonin F; Kilisch M; Wermuth JM; Walther N; Balavarca Y; Stahl-Hennig C; Engelke M; Walter L; Bickeböller H; Kube D; Wulf G; Dressel R
EMBO Mol Med; 2015 Nov; 7(11):1480-502. PubMed ID: 26483398
[TBL] [Abstract][Full Text] [Related]
14.
Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
[TBL] [Abstract][Full Text] [Related]
15. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family.
Steinle A; Li P; Morris DL; Groh V; Lanier LL; Strong RK; Spies T
Immunogenetics; 2001; 53(4):279-87. PubMed ID: 11491531
[TBL] [Abstract][Full Text] [Related]
16. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
[TBL] [Abstract][Full Text] [Related]
18. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
19. The Donor Major Histocompatibility Complex Class I Chain-Related Molecule A Allele rs2596538 G Predicts Cytomegalovirus Viremia in Kidney Transplant Recipients.
Rohn H; Tomoya Michita R; Schwich E; Dolff S; Gäckler A; Trilling M; Le-Trilling VTK; Wilde B; Korth J; Heinemann FM; Horn PA; Kribben A; Witzke O; Rebmann V
Front Immunol; 2018; 9():917. PubMed ID: 29867932
[TBL] [Abstract][Full Text] [Related]
20. MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.
Zingoni A; Vulpis E; Cecere F; Amendola MG; Fuerst D; Saribekyan T; Achour A; Sandalova T; Nardone I; Peri A; Soriani A; Fionda C; Mariggiò E; Petrucci MT; Ricciardi MR; Mytilineos J; Cippitelli M; Cerboni C; Santoni A
Front Immunol; 2018; 9():926. PubMed ID: 29765374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
